USA – Fred Hutchinson Cancer Center has received a US$78 million donation from Stuart and Molly Sloan to support research into precision oncology, a field that aims to assess the biological makeup of cancer in each affected individual.
The pledged donation from Stuart and Molly Sloan is the largest in the 47-year history of the Seattle-based research institution.
Stuart Sloan is the founding sponsor of Obliteride, one of Fred Hutch’s major fundraising events which just celebrated its tenth year. Molly Sloan serves on the Fred Hutch advisory board.
The donation will go towards establishing the new institute; constructing a new building on the Fred Hutch campus; and recruiting a scientific leader and endowed chair for the endeavor; as well as supporting postdoctoral fellowships, sequencing projects, and other investments.
The gift will further advance Fred Hutch’s work in precision oncology, which integrates fundamental biology, technology, immunology, data science, and clinical experience into strategies to prevent, detect and treat cancer.
The new institute will be called the Stuart and Molly Sloan Precision Oncology Institute.
The effort will enable Fred Hutch to build up another area of cancer research to augment its strength in immuno-oncology, said Dr. Thomas Lynch, Fred Hutch’s president and director.
“Understanding cancer pathways, the genes, and the tumor microenvironment and the microbiome all come to play in understanding precision oncology,” Lynch said.
The gift will further advance Fred Hutch’s work in precision oncology, which integrates fundamental biology, technology, immunology, data science, and clinical experience into strategies to prevent, detect and treat cancer.
As an example, Lynch pointed to research showing that some tumors with mutations in a DNA repair enzyme have stronger responses to certain immunotherapies.
The example shows how precision oncology can identify an abnormal gene and an immune therapy can deliver the knockout blow.
Fred Hutch’s recent merger inspired Sloan’s to make the contribution
Lynch said the Sloan’s were heartened by a recent agreement to align cancer care at Fred Hutch and University of Washington Medicine, and coordinate research more closely between them.
“With this gift, we want to expand the development of precision therapies for more cancers and bring hope to everyone who is unfortunately experiencing cancer,” Stuart Sloan said in a statement released Thursday.
“Everyone has been touched by cancer, and too many lives have been lost to this terrible disease,” Molly Sloan said.
“We hope this donation inspires others to join Fred Hutch’s efforts to continue to be a place where more cures and new treatments are discovered and, ultimately, we collectively put an end to cancer.”
The gift will fund translational and clinical research. It differs from some other gifts by also supporting basic science, Lynch said.
In addition, it will enable Fred Hutch researchers to build on ongoing collaborations with Seattle’s Brotman Baty Institute for Precision Medicine, which has a broader focus.
Planning for the new 390,000-square-foot Fred Hutch building to support the new institute will start this fall. “This is going to be an extremely appealing place to work for scientists in the future,” Lynch said.
Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE
